Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | CDK1 | P06493 | 9/20 | 0.54 |
| ▸ | CDK2 | P24941 | 9/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.54 |
| ▸ | CDK7 | P50613 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916666 | 0.84 | STK17A (0.60) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL1916967 | 0.82 | GSK3B (0.68) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL4579849 | 0.77 | CDK1 (0.44) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL4577993 | 0.74 | AURKA (0.48) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL12390723 | 0.74 | CDK1 (0.62) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL1916711 | 0.73 | STK17A (0.57) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL30431890 | 0.72 | GSK3B (0.46) | KDRCDK1CDK2CYP3A4GSK3B | |
| SCHEMBL3932334 | 0.72 | CDK1 (0.82) | KDRCDK1CDK2CA2CDK4 | |
| SCHEMBL5408199 | 0.71 | STK17A (0.62) | KDRCDK1CDK2MEN1CYP1A2 | |
| SCHEMBL4578774 | 0.71 | CDK1 (0.74) | KDRCDK1CDK2CA2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| US-7456191-B2 | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2008-11-25 | — | — | US | disclosed |
| EP-1861378-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| WO-2006099974-A1 | N-ARYL-SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229325-A1 | N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | CDK2, FLT1, CDK4 | KDR 11/4885CDK1 6/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.